$TGTX
TG THERAPEUTICS, INC.

2014 Q4 Form 10-Q Financial Statement

#000114420414068736 Filed on November 14, 2014

View on sec.gov

Income Statement

Concept 2014 Q4 2014 Q3 2013 Q3
Revenue $38.10K $38.10K $38.10K
YoY Change -4.76% 0.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.620M $3.790M $1.380M
YoY Change 147.95% 174.64% 20.0%
% of Gross Profit
Research & Development $15.14M $13.69M $3.310M
YoY Change 302.66% 313.7% 112.04%
% of Gross Profit
Depreciation & Amortization $0.00 $0.00 $0.00
YoY Change
% of Gross Profit
Operating Expenses $18.76M $17.48M $4.686M
YoY Change 260.06% 273.01% 72.63%
Operating Profit -$17.44M -$4.647M
YoY Change 275.25% 71.22%
Interest Expense -$80.00K $234.8K $240.5K
YoY Change -103.64% -2.39% 5.23%
% of Operating Profit
Other Income/Expense, Net $0.00 -$11.82K $91.22K
YoY Change -100.0% -112.96% 2166.39%
Pretax Income -$18.80M -$17.45M -$4.556M
YoY Change 232.16% 283.0% 68.11%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$18.80M -$17.45M -$4.556M
YoY Change 232.09% 283.02% 85.04%
Net Earnings / Revenue -49340.93% -45808.4% -11959.77%
Basic Earnings Per Share
Diluted Earnings Per Share -$482.4K -$510.4K -$164.7K
COMMON SHARES
Basic Shares Outstanding 43.96M shares 38.12M shares 33.28M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2014 Q4 2014 Q3 2013 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $78.80M $67.20M $50.20M
YoY Change 94.57% 33.86% 188.51%
Cash & Equivalents $55.71M $53.23M $50.18M
Short-Term Investments $23.10M $14.00M
Other Short-Term Assets $174.0K $258.7K $118.4K
YoY Change 263.89% 118.45% -93.42%
Inventory
Prepaid Expenses
Receivables $0.00
Other Receivables $100.0K
Total Short-Term Assets $85.22M $76.67M $50.61M
YoY Change 101.44% 51.47% 163.61%
LONG-TERM ASSETS
Property, Plant & Equipment $20.36K $0.00 $3.829K
YoY Change 256.02% -100.0%
Goodwill $799.4K $799.4K $799.4K
YoY Change 0.0% 0.0%
Intangibles
YoY Change
Long-Term Investments $0.00 $0.00
YoY Change -100.0%
Other Assets $137.1K $71.25K $85.12K
YoY Change 61.07% -16.29%
Total Long-Term Assets $1.532M $834.2K $3.686M
YoY Change -73.63% -77.37% -38.57%
TOTAL ASSETS
Total Short-Term Assets $85.22M $76.67M $50.61M
Total Long-Term Assets $1.532M $834.2K $3.686M
Total Assets $86.75M $77.50M $54.30M
YoY Change 80.3% 42.73% 115.47%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.000M $8.000M $4.300M
YoY Change -16.67% 86.05% 138.89%
Accrued Expenses $700.0K $600.0K $500.0K
YoY Change 0.0% 20.0% 400.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $300.0K $200.0K $700.0K
YoY Change -57.14% -71.43% 0.0%
Total Short-Term Liabilities $5.121M $8.900M $5.678M
YoY Change -18.93% 56.74% 89.27%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $2.300M
YoY Change -100.0% -100.0% -47.73%
Other Long-Term Liabilities $1.500M $1.600M $1.700M
YoY Change -11.76% -5.88%
Total Long-Term Liabilities $1.500M $1.600M $4.000M
YoY Change -16.67% -60.0% -9.09%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.121M $8.900M $5.678M
Total Long-Term Liabilities $1.500M $1.600M $4.000M
Total Liabilities $6.645M $10.50M $9.662M
YoY Change -17.53% 8.68% -39.24%
SHAREHOLDERS EQUITY
Retained Earnings -$95.19M -$76.39M
YoY Change 141.56%
Common Stock $44.97K $41.48K $33.41K
YoY Change 30.98% 24.14%
Preferred Stock
YoY Change
Treasury Stock (at cost) $234.3K $234.3K $84.54K
YoY Change 0.0% 177.2%
Treasury Stock Shares 41.31K shares 41.31K shares 13.53K shares
Shareholders Equity $80.10M $67.10M $44.60M
YoY Change
Total Liabilities & Shareholders Equity $86.75M $77.54M $54.30M
YoY Change 80.3% 42.81% 115.47%

Cashflow Statement

Concept 2014 Q4 2014 Q3 2013 Q3
OPERATING ACTIVITIES
Net Income -$18.80M -$17.45M -$4.556M
YoY Change 232.09% 283.02% 85.04%
Depreciation, Depletion And Amortization $0.00 $0.00 $0.00
YoY Change
Cash From Operating Activities -$15.11M -$8.050M -$1.160M
YoY Change 213.49% 593.97% -61.2%
INVESTING ACTIVITIES
Capital Expenditures -$20.00K $0.00 $0.00
YoY Change 100.0%
Acquisitions
YoY Change
Other Investing Activities -$9.120M $0.00 $0.00
YoY Change 85.37%
Cash From Investing Activities -$9.140M $0.00 $0.00
YoY Change 85.4%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $48.90M $35.00M
YoY Change 39.71%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 26.72M 24.20M 37.93M
YoY Change 66700.0% -36.2%
NET CHANGE
Cash From Operating Activities -15.11M -8.050M -1.160M
Cash From Investing Activities -9.140M 0.000 0.000
Cash From Financing Activities 26.72M 24.20M 37.93M
Net Change In Cash 2.470M 16.15M 36.77M
YoY Change -125.44% -56.08% -1329.77%
FREE CASH FLOW
Cash From Operating Activities -$15.11M -$8.050M -$1.160M
Capital Expenditures -$20.00K $0.00 $0.00
Free Cash Flow -$15.09M -$8.050M -$1.160M
YoY Change 213.72% 593.97% -61.2%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
53225799 USD
CY2014Q3 us-gaap Short Term Investments
ShortTermInvestments
14009644 USD
CY2013Q4 us-gaap Short Term Investments
ShortTermInvestments
0 USD
CY2014Q3 us-gaap Interest Receivable Current
InterestReceivableCurrent
53821 USD
CY2013Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
27169 USD
CY2014Q3 tgtx Prepaid Research And Development
PrepaidResearchAndDevelopment
9117863 USD
CY2013Q4 tgtx Prepaid Research And Development
PrepaidResearchAndDevelopment
1742824 USD
CY2014Q3 us-gaap Other Assets Current
OtherAssetsCurrent
258721 USD
CY2013Q4 us-gaap Other Assets Current
OtherAssetsCurrent
47804 USD
CY2014Q3 us-gaap Assets Current
AssetsCurrent
76665848 USD
CY2013Q4 us-gaap Assets Current
AssetsCurrent
42303263 USD
CY2014Q3 us-gaap Long Term Investments
LongTermInvestments
0 USD
CY2013Q4 us-gaap Long Term Investments
LongTermInvestments
4918897 USD
CY2014Q3 us-gaap Goodwill
Goodwill
799391 USD
CY2013Q4 us-gaap Goodwill
Goodwill
799391 USD
CY2014Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
71251 USD
CY2013Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
85121 USD
CY2014Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
7967548 USD
CY2013Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
4764502 USD
CY2014Q3 tgtx Warrant Or Right Outstanding Weighted Average Exercise Price
WarrantOrRightOutstandingWeightedAverageExercisePrice
1.03
CY2014Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2013Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2014Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2013Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2014Q3 us-gaap Common Stock Value
CommonStockValue
41481 USD
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
34336 USD
CY2014Q3 tgtx Contingently Issuable Shares
ContingentlyIssuableShares
6 USD
CY2013Q4 tgtx Contingently Issuable Shares
ContingentlyIssuableShares
6 USD
CY2014Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
143661893 USD
CY2013Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
79658490 USD
CY2014Q3 us-gaap Treasury Stock Value
TreasuryStockValue
234337 USD
CY2013Q4 us-gaap Treasury Stock Value
TreasuryStockValue
234337 USD
CY2014Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-76388851 USD
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-39404003 USD
CY2014Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
67080192 USD
CY2013Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
40054492 USD
CY2014Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
77544253 USD
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
48112390 USD
CY2014Q3 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
6445474 USD
CY2013Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
554069 USD
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9994297 shares
CY2014Q3 us-gaap Cash
Cash
46780325 USD
CY2013Q4 us-gaap Cash
Cash
39931397 USD
CY2013Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
64529 USD
CY2013Q4 us-gaap Notes Payable Fair Value Disclosure
NotesPayableFairValueDisclosure
64529 USD
CY2014Q3 us-gaap Notes Payable
NotesPayable
183144 USD
CY2013Q4 us-gaap Notes Payable
NotesPayable
742307 USD
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9100404 shares
tgtx Period Anticipated Sufficient To Fund Operating Cash Flow
PeriodAnticipatedSufficientToFundOperatingCashFlow
P24M
CY2014Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
67289264 USD
tgtx Cash Equivalents Maturity Period
CashEquivalentsMaturityPeriod
three months or less
CY2014Q3 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
183144 USD
CY2014Q3 us-gaap Notes Payable Fair Value Disclosure
NotesPayableFairValueDisclosure
183144 USD
CY2013Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
64529 USD
tgtx Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Interest Accrued Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInterestAccruedIncludedInEarnings
695914 USD
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
-577299 USD
CY2014Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
183144 USD
CY2014Q3 us-gaap Debt Instrument Interest Rate Effective Percentage
DebtInstrumentInterestRateEffectivePercentage
0.05 pure
CY2013Q4 us-gaap Debt Instrument Interest Rate Effective Percentage
DebtInstrumentInterestRateEffectivePercentage
0.05 pure
CY2014Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
19310000 USD
CY2011Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
16876000 USD
CY2013Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
18614000 USD
CY2011Q4 us-gaap Debt Instrument Fair Value
DebtInstrumentFairValue
3287700 USD
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
46591 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
0 shares
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
33000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
0 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
397 shares
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
13194 shares
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
4194 shares
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4194 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
46.37
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
4.40
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
4457.57
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
18.62
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
49.14
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
49.14
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y6M
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y9M11D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y7M24D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y7M24D
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 USD
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
81510 USD
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
25080 USD
CY2014Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
25080 USD
CY2014Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2013Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2014Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2013Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2014Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2013Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2014Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2013Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2014Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
41481047 shares
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
34336235 shares
CY2014Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
41439738 shares
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
34294926 shares
CY2014Q3 us-gaap Treasury Stock Shares
TreasuryStockShares
41309 shares
CY2013Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
41309 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
7034957 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
310690 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
903416 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
0 shares
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
6442231 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
4.60
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
8.28
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
7.34
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
0
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
4.76
CY2013Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
5718947 shares
tgtx Warrant Or Right Issued
WarrantOrRightIssued
0 shares
tgtx Warrant Or Right Exercised
WarrantOrRightExercised
1272340 shares
CY2013Q4 tgtx Warrant Or Right Outstanding Weighted Average Exercise Price
WarrantOrRightOutstandingWeightedAverageExercisePrice
1.34
tgtx Warrant Or Right Issued Weighted Average Exercise Price
WarrantOrRightIssuedWeightedAverageExercisePrice
0
tgtx Warrant Or Right Exercised Weighted Average Exercise Price
WarrantOrRightExercisedWeightedAverageExercisePrice
2.27
tgtx Warrant Or Right Expired Weighted Average Exercise Price
WarrantOrRightExpiredWeightedAverageExercisePrice
20.92
CY2013Q4 tgtx Warrant Or Right Aggregate Intrinsic Value
WarrantOrRightAggregateIntrinsicValue
14809030 USD
CY2014Q3 tgtx Warrant Or Right Aggregate Intrinsic Value
WarrantOrRightAggregateIntrinsicValue
42811487 USD
us-gaap Share Based Compensation
ShareBasedCompensation
16066856 USD
CY2014Q3 us-gaap Share Based Compensation
ShareBasedCompensation
4096572 USD
CY2014Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2014Q3 tgtx Share Based Compensation Non Employee Stock Options Outstanding
ShareBasedCompensationNonEmployeeStockOptionsOutstanding
9000 shares
tgtx Stock Issued During Period Shares New Issues Shelf Registration Statement
StockIssuedDuringPeriodSharesNewIssuesShelfRegistrationStatement
67000000 USD
CY2014Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
48900000 USD
CY2014Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
0 USD
CY2013Q4 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
190017 USD
CY2014Q3 us-gaap Deferred Revenue
DeferredRevenue
1714000 USD
CY2013Q4 us-gaap Deferred Revenue
DeferredRevenue
1829000 USD
tgtx Additional Amount Receivable On Achievement Of Pre Specified Milestones
AdditionalAmountReceivableOnAchievementOfPreSpecifiedMilestones
5000000 USD
CY2012 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
330000 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
39645778 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
41915820 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
12740333 USD
us-gaap Business Acquisitions Purchase Price Allocation Year Of Acquisition Description
BusinessAcquisitionsPurchasePriceAllocationYearOfAcquisitionDescription
license revenue on a straight-line basis over the life of the agreement, which is through the expiration of the last licensed patent right or 15 years after the first commercial sale of a product in such country, unless the agreement is earlier terminated
CY2012 us-gaap Proceeds From Fees Received
ProceedsFromFeesReceived
2000000 USD
us-gaap Licenses Revenue
LicensesRevenue
114286 USD
us-gaap Licenses Revenue
LicensesRevenue
114286 USD
CY2013Q3 us-gaap Licenses Revenue
LicensesRevenue
38096 USD
CY2014Q3 us-gaap Licenses Revenue
LicensesRevenue
38096 USD
tgtx Non Cash Stock Expense
NonCashStockExpense
0 USD
tgtx Non Cash Stock Expense
NonCashStockExpense
5350094 USD
CY2013Q3 tgtx Non Cash Stock Expense
NonCashStockExpense
0 USD
CY2014Q3 tgtx Non Cash Stock Expense
NonCashStockExpense
4138844 USD
tgtx Non Cash Compensation Research And Development Expenses
NonCashCompensationResearchAndDevelopmentExpenses
892313 USD
tgtx Non Cash Compensation Research And Development Expenses
NonCashCompensationResearchAndDevelopmentExpenses
6402296 USD
CY2013Q3 tgtx Non Cash Compensation Research And Development Expenses
NonCashCompensationResearchAndDevelopmentExpenses
171442 USD
CY2014Q3 tgtx Non Cash Compensation Research And Development Expenses
NonCashCompensationResearchAndDevelopmentExpenses
1200575 USD
us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
9014776 USD
us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
13197183 USD
CY2013Q3 us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
3138119 USD
CY2014Q3 us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
8352154 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9907089 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
24949573 USD
CY2013Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3309561 USD
CY2014Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13691573 USD
tgtx Non Cash Compensation General And Administrative Expenses
NonCashCompensationGeneralAndAdministrativeExpenses
3363687 USD
tgtx Non Cash Compensation General And Administrative Expenses
NonCashCompensationGeneralAndAdministrativeExpenses
9664560 USD
CY2013Q3 tgtx Non Cash Compensation General And Administrative Expenses
NonCashCompensationGeneralAndAdministrativeExpenses
825313 USD
CY2014Q3 tgtx Non Cash Compensation General And Administrative Expenses
NonCashCompensationGeneralAndAdministrativeExpenses
2895997 USD
us-gaap Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
1833733 USD
us-gaap Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
2500121 USD
CY2013Q3 us-gaap Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
550639 USD
CY2014Q3 us-gaap Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
889872 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5197420 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12164681 USD
CY2013Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1375952 USD
CY2014Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3785869 USD
us-gaap Operating Expenses
OperatingExpenses
15104509 USD
us-gaap Operating Expenses
OperatingExpenses
37114254 USD
CY2013Q3 us-gaap Operating Expenses
OperatingExpenses
4685513 USD
CY2014Q3 us-gaap Operating Expenses
OperatingExpenses
17477442 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-14990223 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-36999968 USD
CY2013Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-4647417 USD
CY2014Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-17439346 USD
us-gaap Interest Income Other
InterestIncomeOther
15054 USD
us-gaap Interest Income Other
InterestIncomeOther
38308 USD
CY2013Q3 us-gaap Interest Income Other
InterestIncomeOther
12375 USD
CY2014Q3 us-gaap Interest Income Other
InterestIncomeOther
12107 USD
us-gaap Other Income
OtherIncome
0 USD
us-gaap Other Income
OtherIncome
95427 USD
CY2013Q3 us-gaap Other Income
OtherIncome
0 USD
CY2014Q3 us-gaap Other Income
OtherIncome
0 USD
us-gaap Interest Expense
InterestExpense
712016 USD
us-gaap Interest Expense
InterestExpense
695914 USD
CY2013Q3 us-gaap Interest Expense
InterestExpense
240530 USD
CY2014Q3 us-gaap Interest Expense
InterestExpense
234787 USD
tgtx Change In Fair Value Of Notes Payable
ChangeInFairValueOfNotesPayable
210052 USD
tgtx Change In Fair Value Of Notes Payable
ChangeInFairValueOfNotesPayable
-118615 USD
CY2014Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
34188108 shares
tgtx Change In Fair Value Of Non Current Note Payable
ChangeInFairValueOfNonCurrentNotePayable
872827 USD
tgtx Change In Fair Value Of Non Current Note Payable
ChangeInFairValueOfNonCurrentNotePayable
577299 USD
CY2013Q3 tgtx Change In Fair Value Of Non Current Note Payable
ChangeInFairValueOfNonCurrentNotePayable
319377 USD
CY2014Q3 tgtx Change In Fair Value Of Non Current Note Payable
ChangeInFairValueOfNonCurrentNotePayable
210857 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
175865 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
15120 USD
CY2013Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
91222 USD
CY2014Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-11823 USD
us-gaap Profit Loss
ProfitLoss
-14814358 USD
us-gaap Profit Loss
ProfitLoss
-36984848 USD
CY2013Q3 us-gaap Profit Loss
ProfitLoss
-4556195 USD
CY2014Q3 us-gaap Profit Loss
ProfitLoss
-17451169 USD
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.62
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.14
CY2013Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.16
CY2014Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.51
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
24057200 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
32436420 shares
CY2013Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
27684802 shares
tgtx Stock Issued During Period Value Exercise Of Warrants
StockIssuedDuringPeriodValueExerciseOfWarrants
2890305 USD
us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
0 USD
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
16791408 USD
us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
16066856 USD
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
5350094 USD
us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
1344440 USD
us-gaap Extinguishment Of Debt Gain Loss Net Of Tax
ExtinguishmentOfDebtGainLossNetOfTax
0 USD
us-gaap Extinguishment Of Debt Gain Loss Net Of Tax
ExtinguishmentOfDebtGainLossNetOfTax
95427 USD
us-gaap Share Based Compensation
ShareBasedCompensation
4256000 USD
tgtx Shares Issued In Connection With In Licensing Agreement
SharesIssuedInConnectionWithInLicensingAgreement
0 USD
tgtx Shares Issued In Connection With In Licensing Agreement
SharesIssuedInConnectionWithInLicensingAgreement
5350094 USD
us-gaap Depreciation
Depreciation
634 USD
us-gaap Depreciation
Depreciation
2454 USD
us-gaap Investment Income Amortization Of Premium
InvestmentIncomeAmortizationOfPremium
0 USD
us-gaap Investment Income Amortization Of Premium
InvestmentIncomeAmortizationOfPremium
127260 USD
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-1589950 USD
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
7585956 USD
us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
0 USD
us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
26652 USD
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
85121 USD
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-13870 USD
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
3412916 USD
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
3269629 USD
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
49240 USD
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
-94590 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-114286 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-114286 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-5915077 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-19952981 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3299 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4498 USD
tgtx Investment In Heldtomaturity Shortterm Securities
InvestmentInHeldtomaturityShorttermSecurities
0 USD
tgtx Investment In Heldtomaturity Shortterm Securities
InvestmentInHeldtomaturityShorttermSecurities
9218008 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-3299 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-9222506 USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
1997498 USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
2890305 USD
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
0 USD
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
677778 USD
tgtx Net Proceeds From Shares New Issues Overallotments
NetProceedsFromSharesNewIssuesOverallotments
37648280 USD
tgtx Net Proceeds From Shares New Issues Overallotments
NetProceedsFromSharesNewIssuesOverallotments
39558093 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
33727402 USD
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16455995 USD
CY2013Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
50183397 USD
dei Document Type
DocumentType
10-Q
dei Amendment Flag
AmendmentFlag
false
dei Document Period End Date
DocumentPeriodEndDate
2014-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2014
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Registrant Name
EntityRegistrantName
TG THERAPEUTICS, INC.
dei Entity Central Index Key
EntityCentralIndexKey
0001001316
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
dei Trading Symbol
TradingSymbol
TGTX
CY2014Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
43964350 shares
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
145200 USD
CY2014Q3 us-gaap Payments To Acquire Lease Receivables
PaymentsToAcquireLeaseReceivables
80000 USD
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
145200 USD
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
565191 USD
tgtx Stock Issued During Period Value Market Public Offering
StockIssuedDuringPeriodValueMarketPublicOffering
22766685 USD
CY2014Q3 us-gaap Stock Issued During Period Shares Issued For Cash
StockIssuedDuringPeriodSharesIssuedForCash
4850055 shares
CY2014Q3 us-gaap Stock Issued During Period Value Issued For Cash
StockIssuedDuringPeriodValueIssuedForCash
50000000 USD
CY2014Q3 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
10.31
CY2014Q3 tgtx Purchase Price
PurchasePrice
100.00

Files In Submission

Name View Source Status
0001144204-14-068736-index-headers.html Edgar Link pending
0001144204-14-068736-index.html Edgar Link pending
0001144204-14-068736.txt Edgar Link pending
0001144204-14-068736-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tgtx-20140930.xml Edgar Link completed
tgtx-20140930.xsd Edgar Link pending
tgtx-20140930_cal.xml Edgar Link unprocessable
tgtx-20140930_def.xml Edgar Link unprocessable
tgtx-20140930_lab.xml Edgar Link unprocessable
tgtx-20140930_pre.xml Edgar Link unprocessable
v393077_10q.htm Edgar Link pending
v393077_ex10-1.htm Edgar Link pending
v393077_ex31-1.htm Edgar Link pending
v393077_ex31-2.htm Edgar Link pending
v393077_ex32-1.htm Edgar Link pending
v393077_ex32-2.htm Edgar Link pending